The sudden development with TNBC makes Oncosec a bit more interesting. AACR data and special meeting afterwards should shed light on things going forward. If BMY enters the picture now for a TNBC phase II combo partnership with upfront money and exclusive licensing deal in that indication...a bidding war with Merck seems likely. TNBC would probably follow the same path as current PISCES trial with fast track and orphan drug indications. $20 buyout price would be very reasonable. Good PISCES data as well as TNBC confirmation data will lead to the start of the planned IST trials and what you have here is a blossoming Oncosec primed for the buyout.
News 
Market Data 
Discover 
AI
